Cullen/Frost Bankers, Inc. Biogen Inc. Transaction History

Cullen/Frost Bankers, Inc.

$7.23 Billion
Q3 2024

A detailed history of Cullen/Frost Bankers, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 50 shares of BIIB stock, worth $7,509. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 100 50.0%

Holding current value

$7,509

Previous $23,000 60.87%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$189.07 - $236.8 $9,453 - $11,840	-50 Reduced 50.0%	50 $9,000
Q2 2024 Aug 05, 2024	SELL	$190.52 - $236.72 $5,525 - $6,864	-29 Reduced 22.48%	100 $23,000
Q1 2024 May 10, 2024	BUY	$212.02 - $267.71 $1,484 - $1,873	7 Added 5.74%	129 $27,000
Q4 2023 Feb 06, 2024	SELL	$222.59 - $267.94 $33,388 - $40,191	-150 Reduced 55.15%	122 $31,000
Q2 2023 Aug 04, 2023	SELL	$275.25 - $318.06 $2,752 - $3,180	-10 Reduced 3.55%	272 $77,000
Q4 2022 Feb 13, 2023	SELL	$252.44 - $306.72 $39,885 - $48,461	-158 Reduced 35.91%	282 $78,000
Q3 2022 Nov 07, 2022	SELL	$194.69 - $268.46 $415,857 - $573,430	-2,136 Reduced 82.92%	440 $117,000
Q2 2022 Aug 05, 2022	SELL	$187.54 - $223.02 $41,821 - $49,733	-223 Reduced 7.97%	2,576 $525,000
Q4 2021 Feb 07, 2022	BUY	$223.92 - $287.77 $40,305 - $51,798	180 Added 6.87%	2,799 $672,000
Q3 2021 Nov 04, 2021	SELL	$282.99 - $369.05 $45,561 - $59,417	-161 Reduced 5.79%	2,619 $741,000
Q2 2021 Aug 05, 2021	SELL	$259.0 - $414.71 $26,159 - $41,885	-101 Reduced 3.51%	2,780 $963,000
Q1 2021 May 05, 2021	SELL	$242.95 - $284.63 $8,260 - $9,677	-34 Reduced 1.17%	2,881 $806,000
Q4 2020 Feb 08, 2021	SELL	$236.26 - $355.63 $124,272 - $187,061	-526 Reduced 15.29%	2,915 $714,000
Q3 2020 Nov 05, 2020	BUY	$264.77 - $305.71 $43,422 - $50,136	164 Added 5.0%	3,441 $976,000
Q2 2020 Aug 05, 2020	BUY	$258.66 - $342.55 $700,968 - $928,310	2,710 Added 477.95%	3,277 $877,000
Q1 2020 May 01, 2020	SELL	$268.85 - $341.04 $9,409 - $11,936	-35 Reduced 5.81%	567 $179,000
Q4 2019 Feb 06, 2020	SELL	$220.06 - $304.07 $286,958 - $396,507	-1,304 Reduced 68.42%	602 $179,000
Q3 2019 Nov 01, 2019	SELL	$217.44 - $243.88 $26,310 - $29,509	-121 Reduced 5.97%	1,906 $444,000
Q2 2019 Aug 01, 2019	SELL	$219.29 - $241.72 $62,497 - $68,890	-285 Reduced 12.33%	2,027 $474,000
Q1 2019 Apr 30, 2019	SELL	$216.71 - $338.96 $6,501 - $10,168	-30 Reduced 1.28%	2,312 $540,000
Q4 2018 Feb 06, 2019	SELL	$278.5 - $352.75 $519,959 - $658,584	-1,867 Reduced 44.36%	2,342 $704,000
Q3 2018 Oct 29, 2018	SELL	$293.51 - $383.83 $1.7 Million - $2.22 Million	-5,778 Reduced 57.86%	4,209 $1.49 Million
Q2 2018 Jul 27, 2018	SELL	$257.52 - $306.91 $1.07 Million - $1.27 Million	-4,142 Reduced 29.32%	9,987 $2.9 Million
Q1 2018 May 11, 2018	SELL	$260.13 - $367.91 $227,093 - $321,185	-873 Reduced 5.82%	14,129 $3.87 Million
Q4 2017 Jan 31, 2018	SELL	$307.64 - $344.58 $173,508 - $194,343	-564 Reduced 3.62%	15,002 $4.78 Million
Q3 2017 Nov 02, 2017	BUY	$281.15 - $329.69 $4.38 Million - $5.13 Million	15,566	15,566 $4.87 Million

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.

Account

Cullen/Frost Bankers, Inc. Biogen Inc. Transaction History